-+ 0.00%
-+ 0.00%
-+ 0.00%

What Ryman Healthcare Doubters Saw Before The Drop

Simply Wall St·11/15/2026 13:22:41
Listen to the news

Ryman Healthcare has been busy reshaping its balance sheet, including a NZ$150 million secured bond issue and an operational reset that investors have followed closely. For Ryman Healthcare shareholders, the loss from the start of the year was 36.1%, including dividends. If you had committed fresh capital on 1 January 2026, that outcome raises a blunt question: were the early bullish and bearish arguments on record then enough to judge whether this reset was worth backing?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

The easy part of this move is behind Ryman Healthcare. Zero in on 196 high quality undervalued stocks for companies trading below our estimates.

The Argument Ryman Healthcare Investors Faced

The shares cost NZ$2.91 at the start of the period, and anyone looking at Ryman Healthcare then was weighing two sharply different stories about what came next.

The bullish narrative saw a fair value of NZ$3.50 and relied on a 10.2% revenue growth assumption together with profit margins lifting to 49.6%. That view rested on an operational overhaul and higher deferred management fees supporting stronger earnings.

The bearish case pointed to a fair value of NZ$2.51 and expected 6.4% annual revenue growth, but also a heavy drag from interest rate risk. It treated tighter regulation and housing market exposure as live threats to future cash generation and new village projects.

NZSE:RYM Trailing 12-Month Earnings & Revenue History as at Nov 2026
NZSE:RYM Trailing 12-Month Earnings & Revenue History as at Nov 2026

What The Results Changed For Ryman Healthcare

The six year secured bond raise of NZ$150 million, backed by low gearing and improved cash flow, supported the bullish view that Ryman Healthcare could repair its balance sheet. The H2 2026 report showed revenue rising to NZ$441.003 million and the loss narrowing to NZ$126.151 million, with net margin improving to a smaller loss of 28.6%. Profitability was still not proven, so the evidence cut both ways.

The original split between bull and bear arguments really hinged on whether cash generation and margins would move together. For a different stock, you would track the change in free cash flow, debt levels, and net margin against any promised reset before leaning on a growth story.

What Ryman Healthcare’s Drop Now Asks You To Believe

Today Ryman Healthcare trades at NZ$1.89, well below the NZ$2.91 level from the start of the year. The analyst consensus Narrative on Simply Wall St places its Fair Value above the current price, based on a reset toward recurring, care led earnings and a lighter development pipeline.

The same Narrative argues that demand trends, village economics, and a leaner cost base could support steadier cash generation despite housing and regulatory risks. For the recent fall to look like an opening rather than a warning, a buyer must believe that this reset model can translate into sustained, cash backed earnings.

"The reset of retirement living economics, with new residents on a 30% deferred management fee and weekly fees that are 63% higher on unit turnover and a growing share of the portfolio moving to these terms by FY29, points to a larger future revenue pool and higher unit level earnings."

The price and this Narrative do not agree. → Uncover what this Narrative says Ryman Healthcare is actually worth

Go Straight To The Source

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

  • Company 1 - 37% below our estimate - sells peripherals into gaming and video collaboration markets that kept ordering through a supply shock.
  • Company 2 - 20% below our estimate - supplies antibiotic-eluting bone grafts hospitals adopt as infection procedures shift to shorter drug courses.
  • Company 3 - 48% below our estimate - licenses forensic software that existing customers upgrade to higher priced tiers for recurring contracts.

Three companies from the same screener. Open every one of the 198 solid balance sheet companies →